Health Care • Biotechnology: Pharmaceutical Preparations
$4.94 ▼ -0.01
(-0.20%)
MKT CAP: $7.7M • VOL: 70.9K
52W L $4 52W H $14
ROARABLE / RQD
D- • 37/100
PIOTROSKI
1 / 9
CURX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 |
|---|---|---|
| Revenue (Total Sales) | $0 | $0 |
| YoY Revenue Growth % | — | — |
| Gross Profit | — | — |
| Gross Margin % | — | — |
| Research & Development (R&D) | — | — |
| Operating Income (EBIT) | -$4.2M | -$365.1K |
| Operating Margin % | — | — |
| Net Income (GAAP) | -$4.2M | -$361.5K |
| EBITDA (Normalized) | — | — |
| Diluted EPS ($/sh) | — | — |
| Operating Cash Flow (OCF) | -$10.5M | -$555.6K |
| Capital Expenditures (CapEx) | — | — |
| Free Cash Flow (FCF) | -$10.5M | -$555.6K |
| FCF Margin % | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% |
| Cash & Short-Term Equivalents | $5.0M | — |
| Total Debt (Short + Long Term) | — | — |
| Total Stockholders' Equity | $11.2M | $503.4K |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CURX.